EXAI vs. RLAY, ABCL, SDGR, ADMA, CGON, RXRX, NVAX, KYMR, BEAM, and FUSN
Should you be buying Exscientia stock or one of its competitors? The main competitors of Exscientia include Relay Therapeutics (RLAY), AbCellera Biologics (ABCL), Schrödinger (SDGR), ADMA Biologics (ADMA), CG Oncology (CGON), Recursion Pharmaceuticals (RXRX), Novavax (NVAX), Kymera Therapeutics (KYMR), Beam Therapeutics (BEAM), and Fusion Pharmaceuticals (FUSN). These companies are all part of the "medical" sector.
Exscientia (NASDAQ:EXAI) and Relay Therapeutics (NASDAQ:RLAY) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their community ranking, institutional ownership, risk, analyst recommendations, valuation, profitability, earnings, dividends and media sentiment.
Relay Therapeutics received 30 more outperform votes than Exscientia when rated by MarketBeat users. Likewise, 60.94% of users gave Relay Therapeutics an outperform vote while only 36.00% of users gave Exscientia an outperform vote.
Exscientia has a net margin of -666.80% compared to Relay Therapeutics' net margin of -1,263.49%. Exscientia's return on equity of -34.59% beat Relay Therapeutics' return on equity.
Exscientia has higher revenue and earnings than Relay Therapeutics. Exscientia is trading at a lower price-to-earnings ratio than Relay Therapeutics, indicating that it is currently the more affordable of the two stocks.
Exscientia has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Relay Therapeutics has a beta of 1.68, suggesting that its share price is 68% more volatile than the S&P 500.
Exscientia currently has a consensus target price of $9.75, indicating a potential upside of 86.78%. Relay Therapeutics has a consensus target price of $22.20, indicating a potential upside of 243.12%. Given Relay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Relay Therapeutics is more favorable than Exscientia.
41.6% of Exscientia shares are held by institutional investors. Comparatively, 97.0% of Relay Therapeutics shares are held by institutional investors. 16.4% of Exscientia shares are held by company insiders. Comparatively, 4.3% of Relay Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
In the previous week, Exscientia had 12 more articles in the media than Relay Therapeutics. MarketBeat recorded 18 mentions for Exscientia and 6 mentions for Relay Therapeutics. Relay Therapeutics' average media sentiment score of 1.61 beat Exscientia's score of 0.40 indicating that Relay Therapeutics is being referred to more favorably in the news media.
Summary
Relay Therapeutics beats Exscientia on 10 of the 18 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding EXAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Exscientia Competitors List
Related Companies and Tools
